Development of a myeloproliferative disorder in a patient with monoclonal gammopathy of undetermined significance secreting immunoglobulin of the M class and treated with thalidomide and anti-CD20 monoclonal antibody.
Kyrtsonis
M C
MC
Kokoris
S I
SI
Kontopidou
F N
FN
Siakantaris
M P
MP
Kittas
C
C
Pangalis
G A
GA
D000368:Aged; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D018450:Disease Progression; D006801:Humans; D007116:Immunization, Passive; D007075:Immunoglobulin M / Q000097:blood; D007145:Immunoglobulin kappa-Chains / Q000097:blood; D008297:Male; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D009196:Myeloproliferative Disorders / Q000139:chemically induced*; D010266:Paraproteins / Q000032:analysis; D013792:Thalidomide / Q000009:adverse effects* / Q000627:therapeutic use; D013922:Thrombocytosis / Q000139:chemically induced*; D008258:Waldenstrom Macroglobulinemia / Q000209:etiology*
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D007075:Immunoglobulin M; D007145:Immunoglobulin kappa-Chains; D010266:Paraproteins; D013792:Thalidomide